FAST PV and mGFR™ Technology in Congestive Heart Failure

NACompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

January 10, 2019

Primary Completion Date

August 17, 2019

Study Completion Date

August 17, 2019

Conditions
CHF
Interventions
DEVICE

VFI

The IV-administered visible fluorescent injectate (VFI)™ agent comprises a mixture of 2 different molecular weight carboxymethyl dextran molecules (5 kD and 150 kD) with different fluorescent dye molecules attached.

Trial Locations (1)

13353

Charité - Universitätsmedizin Berlin, Berlin

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

FAST BioMedical

INDUSTRY

lead

Charite University, Berlin, Germany

OTHER